• Executive

Chris Riley

Executive Vice President, Biotechnology Group and CEO, Cytiva

Danaher leader Chris Riley

As Executive Vice President of Danaher’s Biotechnology Platform, Chris provides operational and strategic leadership for Cytiva and its portfolio of businesses.
 

Biography

Chris Riley is an experienced business operator and growth-oriented strategist with a track record of innovating and applying the Danaher Business System to global Diagnostics and Life Sciences companies.

Timeline

Chris joined Danaher in 2007 and has served in multiple operating and strategy roles of increasing responsibility.  In 2019, Chris was appointed Danaher Vice President and Group Executive, Diagnostics, and in 2022, he was appointed Danaher Vice President and Group Executive, Genomic Medicines Group.  Prior to joining Danaher, he worked for Boston Consulting Group as a core member of their Operations and Strategy practice areas.

Chris holds a Bachelor of Science with Honors in Mechanical Engineering from the University of Illinois and an MBA from the Kellogg Graduate School of Management at Northwestern University.

Our Cytiva team partners with customers every day to bring innovative therapies to market with less risk, enabling execution from discovery to delivery. We combine our expertise and a broad and deep portfolio to help expand access to life-changing therapies to transform human health.
Chris Riley
Executive Vice President

Get to know our leaders

More from Danaher